Rein Therapeutics, Inc. — fact timeline

Rein Therapeutics, Inc. entered into Underwriting Agreement with Konik Capital Partners, LLC valued at $1.00 per share, before underwriting discounts and commissions (effective 2026-04-30).

“On April 30, 2026, Rein Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Konik Capital Partners, LLC, a division of T.R. Winston & Company, LLC, acting as sole book-running manager, relating to the issuance and sale of 50,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Offering”).”

Rein Therapeutics, Inc. incurred senior notes of $2,875,000 with three institutional investors at 20% original issue discount maturing the earlier of (i) the date of the closing of the next issuance and sale of securities of the Company, in a single transaction or series of related transactions.

“On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).”

Rein Therapeutics, Inc. entered into Purchase Agreement with three institutional investors valued at $2,875,000.

“On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).”

Rein Therapeutics, Inc. entered into Purchase Agreement with Funicular Funds, LP valued at original principal amount of $2,500,000 (effective 2026-01-15).

“On January 15, 2026, Rein Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Funicular Funds, LP, a Delaware limited partnership managed by Cable Car Capital, LP (“Funicular”), pursuant to which the Company issued and sold to Funicular, in a private placement, an unsecured promissory note, dated January 15, 2026, in the original principal amount of $2,500,000 (the “Note”).”

Rein Therapeutics, Inc. incurred loan of $2,500,000 with Funicular Funds, LP at 20% original issue discount maturing the earlier of (i) the date of the closing of the next issuance and sale of securities of the Company, in a single transaction or series of related transactions.

“the Company issued and sold to Funicular, in a private placement, an unsecured promissory note, dated January 15, 2026, in the original principal amount of $2,500,000 (the “Note”)”

Rein Therapeutics, Inc. terminated Standby Equity Purchase Agreement with YA II PN, Ltd. (effective 2025-12-11).

“On December 11, 2025, Rein Therapeutics, Inc. (the “Company”) elected to terminate the Pre-Paid Advance Agreement (the “PPA”) dated July 29, 2025 with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”), and the Standby Equity Purchase Agreement (the “SEPA”) dated July 29, 2025 also entered into with Yorkville.”

Rein Therapeutics, Inc. terminated Pre-Paid Advance Agreement with YA II PN, Ltd. (effective 2025-12-11).

“On December 11, 2025, Rein Therapeutics, Inc. (the “Company”) elected to terminate the Pre-Paid Advance Agreement (the “PPA”) dated July 29, 2025 with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”), and the Standby Equity Purchase Agreement (the “SEPA”) dated July 29, 2025 also entered into with Yorkville.”

Rein Therapeutics, Inc. incurred debt of $1.0 million with YA II PN, Ltd. at 8% maturing 12-month anniversary of their issuance.

“(the “Company”, “we”, “us”) in a Current Report on Form 8-K filed on July 30, 2025, on July 29, 2025 (the “Effective Date”), we entered into a Pre-Paid Advance Agreement (the “PPA”) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”). In accordance with the terms of the PPA, we may request pre-paid advances of up to $6.0 million from Yorkville (each, a “Pre-Paid Advance”) over a 12-month period, subject to certain limitations and conditions set forth in the PPA.”

Rein Therapeutics, Inc. incurred debt of $1.0 million with YA II PN, Ltd. at 8%.

“(the “Company”, “we”, “us”) in a Current Report on Form 8-K filed on July 30, 2025, on July 29, 2025 (the “Effective Date”), we entered into a Pre-Paid Advance Agreement (the “PPA”) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”). In accordance with the terms of the PPA, we may request pre-paid advances of up to $6.0 million from Yorkville (each, a “Pre-Paid Advance”) over a 12-month period, subject to certain limitations and conditions set forth in the PPA.”

Rein Therapeutics, Inc. incurred credit facility of up to $6.0 million with YA II PN, Ltd. at 8%.

“(the “Company”) entered into a Pre-Paid Advance Agreement (the “PPA”) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”). In accordance with the terms of the PPA, the Company may request pre-paid advances of up to $6.0 million from Yorkville (each, a “Pre-Paid Advance”) over a 12-month period, subject to certain limitations and conditions set forth in the PPA.”

Rein Therapeutics, Inc.: Amended quorum requirement to 40% of outstanding shares entitled to vote at stockholder meetings (effective 2025-07-10).

“On July 10, 2025, the Board of Directors (the “Board”) of Rein Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated By-laws (as amended, the “By-laws”), effective immediately, to provide that forty percent (40%) of the shares of capital stock of the Company issued and outstanding and entitled to vote at the meeting, present in person, present by means of remote communication in a manner, if any, authorized by the Board in its sole discretion, or represented by proxy shall constitute a quorum at all meetings of the stockholders for the transaction of business except as otherwise provided by law, the Restated Certificate of Incorporation, as amended, or the By-laws.”

Rein Therapeutics, Inc. engaged CBIZ CPAs P.C. as its auditor.

“On November 1, 2024, CBIZ CPAs P.C. (“CBIZ CPAs”) acquired the attest business of Marcum. On April 16, 2025, following the approval of the Audit Committee of the Board of Directors of the Company, CBIZ CPAs was engaged, effective immediately.”

Marcum LLP resigned as auditor of Rein Therapeutics, Inc..

“Marcum had resigned as the Company’s independent registered public accounting firm, effective immediately.”

Rein Therapeutics, Inc.: Amended and restated bylaws solely to reflect company name change from Aileron Therapeutics, Inc. to Rein Therapeutics, Inc (effective 2025-01-10).

“In connection with the Name Change, the Board also approved an amendment and restatement of the Company’s Amended and Restated Bylaws solely to reflect the Name Change (as amended and restated, the “Amended and Restated Bylaws”) effective as of January 10, 2025.”

Rein Therapeutics, Inc.: Amended certificate of incorporation to change company name from Aileron Therapeutics, Inc. to Rein Therapeutics, Inc (effective 2025-01-10).

“On January 10, 2025, Aileron Therapeutics, Inc. (the “Company”) amended its Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to effect a change of the Company’s name from “Aileron Therapeutics, Inc.” to “Rein Therapeutics, Inc.” (the “Name Change”). The Name Change became effective at 4:00 p.m. Eastern Time on January 10, 2025.”

Timothy M. Cunningham was appointed as Interim Chief Financial Officer at Rein Therapeutics, Inc..

“the Board of Directors of Aileron Therapeutics, Inc. (the “Company”) appointed Timothy M. Cunningham, a consultant at Danforth Advisors, LLC (“Danforth”), as interim chief financial officer, effective as of May 16, 2024.”

Charles Garner departed as Chief Financial Officer at Rein Therapeutics, Inc..

“Mr. Garner's departure from the Company on May 15, 2024.”

Rein Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter, EPS The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarte.

“Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter in 2023. The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarter ended March 31, 2023.”

Rein Therapeutics, Inc. entered into Underwriting Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC valued at combined offering price of $4.68 (effective 2024-05-01).

“On May 1, 2024, Aileron Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC, as underwriter (the “Underwriter”), relating to an underwritten offering (the “Offering”) of 4,273,505 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and accompanying warrants (“Warrants”) to purchase 4,273,505 shares of Common Stock.”

Rein Therapeutics, Inc. reported full year ended December 31, 2023 results: EPS $3.42 per share.

“The basic and diluted net loss per share for the full-year 2023 was $3.42 compared to $6.02 for the full-year 2022.”

Rein Therapeutics, Inc. reported the fourth quarter ended December 31, 2023 results: net income $7.3 million, EPS $1.54 per share.

“Net loss for the quarter ended December 31, 2023, was $7.3 million, compared to $4.5 million for the quarter ended December 31, 2022. The basic and diluted net loss per share for the quarter ended December 31, 2023 was $1.54 compared to $1.00 for the quarter ended December 31, 2022.”

Charles Garner departed as principal financial officer and principal accounting officer at Rein Therapeutics, Inc..

“Separately, the Company and Mr. Garner have agreed that his employment with the Company will end effective as of May 15, 2024.”

Charles Garner was appointed as principal financial officer and principal accounting officer at Rein Therapeutics, Inc..

“the Board of Directors of the Company appointed Charles Garner to serve as the Company’s principal financial officer and principal accounting officer, effective as of March 25, 2024.”

Susan L. Drexler resigned as Interim Chief Financial Officer, principal financial officer and principal accounting officer at Rein Therapeutics, Inc..

“On March 25, 2024, Susan L. Drexler, Interim Chief Financial Officer, principal financial officer and principal accounting officer of Aileron Therapeutics, Inc. (the “Company”), notified the Company of her resignation, effective as of March 25, 2024.”

Brian Windsor was elected as Director at Rein Therapeutics, Inc..

“the Board elected Brian Windsor, Ph.D., as the Chief Executive Officer of the Company and a member of the Board, effective as of March 11, 2024”

Brian Windsor was elected as Chief Executive Officer at Rein Therapeutics, Inc..

“the Board elected Brian Windsor, Ph.D., as the Chief Executive Officer of the Company and a member of the Board, effective as of March 11, 2024”

Manuel C. Alves-Aivado resigned as Chief Executive Officer at Rein Therapeutics, Inc..

“Manuel C. Alves-Aivado, M.D., Ph.D., agreed that his employment with the Company would cease and he would resign from his position as Chief Executive Officer of the Company, effective as of March 11, 2024”

Nolan Sigal resigned as member of the Board of Directors at Rein Therapeutics, Inc..

“On February 29, 2024, Nolan Sigal, M.D., Ph.D., notified Aileron Therapeutics, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company (the “Board”), effective immediately.”

Rein Therapeutics, Inc.: Increased authorized shares of common stock from 45,000,000 to 100,000,000 (effective 2024-02-28).

“The Company filed the Certificate of Amendment to implement the increase in the number of authorized shares, which was effective upon filing, with the Secretary of State of the State of Delaware on February 28, 2024.”

Rein Therapeutics, Inc. engaged Marcum LLP as its auditor.

“On January 10, 2024, the Audit Committee of the Board of Directors of the Company appointed Marcum LLP ("Marcum") as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2023. The Company formally engaged Marcum on January 9, 2024.”

Rein Therapeutics, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 4, 2024, Aileron Therapeutics, Inc., a Delaware corporation (the “Company”), received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company failed to hold its annual meeting of shareholders within twelve (12) months after its fiscal year ended December 31, 2022, as required by Nasdaq Listing Rule 5620(a) (the “Annual Meeting Listing Rule”). The Notice does not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital Market. The Notice states that the Company has 45 calendar”

Rein Therapeutics, Inc.: Filed Certificate of Designation for Series X Non-Voting Convertible Preferred Stock (effective 2023-10-31).

“On October 31, 2023, Aileron filed a Certificate of Designation of Preferences, Rights and Limitations of the Series X Preferred Stock with the Secretary of State of the State of Delaware (the “ Certificate of Designation ”) in connection with the Merger and the Financing referenced in Item 1.01 above.”

Rein Therapeutics, Inc. completed an acquisition involving Lung Therapeutics, Inc. (closed 2023-10-31).

“On October 31, 2023, Aileron completed its acquisition of Lung.”

Rein Therapeutics, Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $18.0 million (effective 2023-10-31).

“Immediately following the closing of the Merger, on October 31, 2023, Aileron entered into a Stock and Warrant Purchase Agreement (the “ Purchase Agreement ”) with a group of accredited investors (the “ Investors ”) led by Bios Partners, the majority shareholder of Lung prior to the closing of the Merger, and including Nantahala Capital, as well as additional undisclosed investors.”

Rein Therapeutics, Inc. entered into Merger Agreement with Lung.

“Pursuant to the Merger Agreement, Aileron has agreed to hold a stockholders’ meeting no later than 120 days after the date on which the closing of the Merger occurs”

Rein Therapeutics, Inc. dismissed PricewaterhouseCoopers LLP as its auditor.

“Aileron dismissed its independent registered public accounting firm, PricewaterhouseCoopers LLP ("PwC"), effective immediately upon the closing of the Merger.”

Josef H. von Rickenbach was appointed as Chairman of the Board at Rein Therapeutics, Inc..

“Following Mr. Bailey's resignation, Josef H. von Rickenbach will serve as the Chairman of the Board.”

William T. McKee resigned as Director at Rein Therapeutics, Inc..

“On October 31, 2023, immediately prior to the Effective Time, Jeffrey A. Bailey, Chairman of the Board, Jodie P. Morrison and William T. McKee resigned from the Board.”

Jodie P. Morrison resigned as Director at Rein Therapeutics, Inc..

“On October 31, 2023, immediately prior to the Effective Time, Jeffrey A. Bailey, Chairman of the Board, Jodie P. Morrison and William T. McKee resigned from the Board.”

Jeffrey A. Bailey resigned as Chairman of the Board at Rein Therapeutics, Inc..

“On October 31, 2023, immediately prior to the Effective Time, Jeffrey A. Bailey, Chairman of the Board, Jodie P. Morrison and William T. McKee resigned from the Board.”

Brian Windsor was appointed as President and Chief Operating Officer at Rein Therapeutics, Inc..

“On October 30, 2023, the Board approved the appointment of Brian Windsor, Ph.D., age 57, to President and Chief Operating Officer of Aileron, effective as of the consummation of the Merger.”

Rein Therapeutics, Inc. announced a restructuring with charges of approximately $1.0 to $1.1 million affecting the Company (reduce the Company’s remaining workforce from nine to three employees).

“nine to three employees. The determination to effect the workforce reduction was made in connection with the Company’s decision, further described below, to terminate its Phase 1b breast cancer trial of ALRN-6924 and further development of ALRN-6924. The workforce reduction is designed to reduce the Company’s operating expenses while the Company explores”

Rein Therapeutics, Inc.: Effected a 1-for-20 reverse stock split and reduced authorized common shares from 300,000,000 to 15,000,000 then multiplied by three to 45,000,000 (effective 2022-11-10).

“On November 10, 2022 (the “Effective Date”), Aileron Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which effected, as of 5:00 p.m. Eastern Time on the Effective Date, a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding common stock, $0.001 par value per share (the “Common Stock”).”

Vojislav Vukovic departed as Chief Medical Officer at Rein Therapeutics, Inc..

“On July 8, 2022, Aileron Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Separation and Release of Claims Agreement with Vojislav Vukovic, M.D., Ph.D. (the “Separation Agreement”), which provides for Dr. Vukovic’s separation of employment as Senior Vice President, Chief Medical Officer of the Company, effective July 8, 2022”

Susan L. Drexler was appointed as interim chief financial officer at Rein Therapeutics, Inc..

“On June 15, 2022, the Board of Directors of Aileron Therapeutics, Inc. (the “Company”) appointed Susan L. Drexler, a consultant at Danforth Advisors, LLC (“Danforth”), as interim chief financial officer, effective as of June 16, 2022.”

Manuel Aivado was appointed as principal financial officer and principal accounting officer at Rein Therapeutics, Inc..

“On June 5, 2022, the Board of Directors of the Company appointed Manuel Aivado, M.D., Ph.D., the Company’s President and Chief Executive Officer to serve as the Company’s principal financial officer and principal accounting officer.”

Richard J. Wanstall resigned as Chief Financial Officer at Rein Therapeutics, Inc..

“Richard J. Wanstall, the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, notified the Company of his resignation, effective May 6, 2022.”

Richard J. Wanstall resigned as Chief Financial Officer at Rein Therapeutics, Inc..

“On April 25, 2022, Richard J. Wanstall, Chief Financial Officer, principal financial officer and principal accounting officer of Aileron Therapeutics, Inc., a Delaware corporation (the “Company”), notified the Company of his resignation, effective May 6, 2022, to pursue another career opportunity.”